A patient with neurogenic thoracic outlet syndrome was initially treated with scalenectomy, first rib resection, and wrapping of the brachial plexus (BP) with amnion membrane (AM) to prevent postoperative adhesions. Twelve months later, at reoperation for recurrent symptoms, the AM was observed to be intact. The BP had no scar tissue around it. Recurrence was due to scarring around the nerve roots superior to the portion of the plexus that had been wrapped with AM. It was concluded that the AM had successfully protected the portion of the BP that had been wrapped. Longer term studies are in progress. (
Surgery for neurogenic thoracic outlet syndrome (NTOS) decompression has a failure rate of 25% to 30%, primarily due to postoperative scar tissue compressing the brachial plexus (BP). 1 Whereas scarring can be prevented by wrapping the BP with physical barriers, successful wrapping materials have not been found to date.
Unpublished anecdotal reports of successful wrapping of peripheral nerve repairs with amnion membrane (AM) have recently appeared. With this in mind, we began employing AM (AlloWrap DS; AlloSource, Centennial, Colo) after thoracic outlet decompression operations.
In June 2017, a patient already in the AM treatment protocol required reoperation 1 year postoperatively for recurrence of NTOS symptoms. The surprising finding of no scarring over the AM at this operation is the subject of this report. The patient has read and given consent to publication of this case report.
CASE REPORT
In June 2016, a 34-year-old neurology technician presented with constant pain in her neck, right trapezius, shoulder, arm, and supraclavicular area plus tenderness in her right anterior chest wall and axilla. She also had constant paresthesia in her right fourth and fifth fingers, daily occipital headaches, and right arm weakness. The symptoms, having developed spontaneously several weeks earlier, had not improved with physical therapy for NTOS and neurogenic pectoralis minor syndrome (NPMS).
Physical examination demonstrated mild tenderness over the right anterior scalene muscle, pectoralis minor muscle, and axilla, with no tenderness on the left side in these areas.
Tinel sign was present on the right over the BP in the neck and over the radial tunnel and carpal tunnel. Through the previous transaxillary incision, adhesive scar tissue was excised, and a piece of AM was placed over the cords of the BP to lessen rescarring. This incision was closed, the neck now prepared, and the previous supraclavicular incision reopened. 
DISCUSSION
The recurrent symptoms for which this patient was reoperated on were not due to a failure of the AM; rather, failure was due to scar formation in the area of an unwrapped portion of the BP at the level of the nerve roots. It pointed out the importance of removing as much of the anterior scalene muscle as is safely possible and wrapping every portion of exposed nerve.
The history of using AM is >100 years old. It began with its use to cover stasis ulcers and burns, then to cover dural defects after brain trauma. [2] [3] [4] [5] AM is immune privileged, meaning that it is not rejected as a foreign body when it is implanted in humans. 6 Amnionic epithelial cells can act like stem cells. They can be converted into any of the three basic germ layers 7 and can perform as ocular stem cells. 8 In addition, AM is anti-inflammatory, antibacterial, antiviral, antiangiogenic, and proapoptotic. It also is a promotor of epithelialization and is nontumorigenic tissue. 9,10 Another unusual property is AM's ability to act as a bridge in promoting axonal regeneration in damaged adult brain. 11 AM has been used in three general types of applications: to prevent adherence of scar tissue to nerve 12 and tendon repairs 13 ; as a dressing to reduce pain and infection and to stimulate epithelialization after burns 14, 15 or trauma while an area recovers from injury; and as a cover to assist in closing defects. AM has been used as a dressing to repair corneas and conjunctiva 16, 17 and to cover injury to the oral or nasal mucosa, pharynx, or tympanic membrane. 18, 19 In this report, processed AM (treated with glutaraldehyde) was used as a barrier to prevent normal scar tissue formations from reaching the BP after thoracic outlet decompression. During the past 2 years, AM has been employed for this purpose in 97 NTOS operations. The first 40 patients have now been observed for 1 year. Their recurrence rate is 5% to date. They must be observed for 24 months before an acceptable long-term result can be established.
From previous studies, it is known that 80% of recurrences will be evident in the first 18 months after thoracic outlet decompression. In these previous studies, the failure rate for thoracic outlet decompression at the 2-year follow-up level was 25% to 30%. This was true for all three surgical approaches: transaxillary first rib resection, supraclavicular scalenectomy, and supraclavicular scalenectomy with first rib resection. 1 Most recurrences were due to scar tissue adherence to the BP regardless of the operative approach; a few were from other associated diagnoses.
The AM used in this patient was treated with glutaraldehyde in its preparation by AlloSource. Although glutaraldehyde inactivates cellular viability, this is not a concern, as the function of the amnion in this application is one of a protective barrier against scar tissue's reaching the BP after implantation. When the AM has finally been degraded after several months, the healing period is over and scar tissue has matured so that it no longer adheres to nerves. This is the explanation for almost all failures of NTOS surgery occurring within the first 24 months. This is the first NTOS patient with AM to undergo reoperation and our first opportunity to examine AM 1 year after surgery. It is impressive that the amnion layer survived the 1-year time interval without obvious degradation. This was the fate of other materials used previously. We assume they were absorbed too quickly to protect the nerves throughout the normal healing time of 12 to 15 months.
Previous antiadhesive materials, synthetic polymer sheets (SurgiWrap [MAST Biosurgery, San Diego, Calif] and Seprafilm [Sanofi-Aventis, Bridgewater, NJ]) that had successfully reduced adhesions in the abdomen, failed to reduce the failure rate after thoracic outlet operations. 20 Glutaraldehyde-treated, double-sided AM (AlloWrap DS) is the first material used to protect the BP from scar tissue that appears to be successful. Although it is too early to know the long-term results, the 1-year results are encouraging. The operating room observations of the AM in this case report give the authors hope that this material will prove helpful to future surgical patients.
Yet to be reported are other successful clinical uses of AM, including wrapping Achilles tendon repairs, covering the ends of amputated nerves to help prevent chronic phantom sensation, and wrapping nerves damaged by extremity tumors (R.M. Wilkins, MD, personal communication). Separately, placing AM over the dura in closing laminectomy sites has reduced postoperative scarring, making reoperations significantly easier and safer (T. Birney, MD, personal communication).
